公开(公告)号：US20170061136A1

公开(公告)日：2017-03-02

申请号：US15253523

申请日：2016-08-31

Applicant: Virginia Commonwealth University Intellectual Property Foundation ,  The Regents of the University of Colorado

Inventor： Carol Fung ,  Bahman Rashidi ,  Tam Vu

IPC: G06F21/57 ,  G06F21/62

CPC classification number: G06F21/577 ,  G06F21/51 ,  G06F21/6218

Abstract: In one example implementation, a method includes receiving, at a computing device, a request to grant a set of requested permissions to an application installed on the computing device, and sending, from the computing device, a permission query request to a recommendation server, where the permission query request includes an identifier for the application, and the set of requested permissions. The method may also include receiving, at the computing device, from the recommendation server, a set of permission recommendations, where the set of permission recommendations indicates whether the recommendation server recommends granting each requested permission from the set of requested permissions. The method may also include displaying the set of requested permissions and the set of permission recommendations, determining a set of granted permissions for the application, granted by a user of the computing device, from the set of requested permissions, and setting the permissions for the application on the computing device using the set of granted permissions.

Abstract translation: 在一个示例实现中，一种方法包括在计算设备处接收向安装在所述计算设备上的应用授予一组所请求的许可的请求，以及从所述计算设备向所述推荐服务器发送许可查询请求， 其中权限查询请求包括应用程序的标识符和所请求的权限集。 该方法还可以包括在计算设备处从推荐服务器接收一组许可建议，其中许可建议集合指示推荐服务器是否建议从所请求的许可的集合中授予每个所请求的许可。 该方法还可以包括显示所请求的许可的集合和一组权限建议，确定由计算设备的用户授予的应用程序的一组已授权的许可权限，从所述一组所请求的权限中，并且为 计算设备上的应用程序使用一组授予的权限。

公开(公告)号：US09527823B2

公开(公告)日：2016-12-27

申请号：US14537124

申请日：2014-11-10

Applicant: Research Triangle Institute ,  Dignity Health ,  Virginia Commonwealth University

Inventor： Frank Ivy Carroll ,  Bruce E. Blough ,  Hernan A. Navarro ,  S. Wayne Mascarella ,  Ana Zamfira Muresan ,  M. Imad Damaj ,  Ronald J. Lukas

IPC: C07D265/32 ,  A61K31/5375

CPC classification number: C07D265/32 ,  A61K31/5375

Abstract: The invention provides hydroxybupropion analogs capable of inhibiting the reuptake of one or more monoamines and/or acting as antagonists at nicotinic acetylcholine receptors. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin and/or may selectively bind to one or more nicotinic acetylcholine receptor subtypes. Such compounds may be used to treat conditions that are responsive to modification of monoamine levels and/or antagonism of nicotinic acetylcholine receptors, including drug dependency, depression, and obesity.

Abstract translation: 本发明提供了能够抑制一种或多种单胺再摄取和/或在烟碱乙酰胆碱受体上作为拮抗剂的羟基安非他丁类似物。 所述化合物可以选择性地结合一种或多种单胺转运蛋白，包括用于多巴胺，去甲肾上腺素和5-羟色胺的单胺转运蛋白和/或可以选择性地结合一种或多种烟碱型乙酰胆碱受体亚型。 这些化合物可用于治疗对单胺水平的修饰和/或烟碱乙酰胆碱受体的拮抗作用有反应的病症，包括药物依赖性，抑郁症和肥胖症。

公开(公告)号：US20160264615A1

公开(公告)日：2016-09-15

申请号：US15042244

申请日：2016-02-12

Applicant: Virginia Commonwealth University

Inventor： Shunlin Ren ,  William M. Pandak

IPC: C07J31/00

CPC classification number: C07J31/006 ,  C07J9/00

Abstract: The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.

Abstract translation: 提供了降低脂质生物合成并增加胆固醇分泌和降解的核胆固醇代谢产物硫酸氢化甾醇5胆甾醇-3β，25-二醇3-硫酸酯，作为降低细胞内和血清胆固醇和/或甘油三酯的药物，并防止 或治疗与这种炎症相关的脂质积聚相关的炎症和病症。 还提供涉及使用该硫酸化氧固醇来治疗与高胆固醇和/或高甘油三酸酯和/或炎症相关的病症（例如高胆固醇血症，高甘油三酯血症，非酒精性脂肪性肝病，动脉粥样硬化等）的方法。

公开(公告)号：US20160206325A1

公开(公告)日：2016-07-21

申请号：US15054973

申请日：2016-02-26

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Kevin Ward ,  Mark Licata

IPC: A61B17/135 ,  A61B17/132

CPC classification number: A61B17/135 ,  A61B17/12 ,  A61B17/1322 ,  A61B17/1325 ,  A61B2017/12004

Abstract: Bleeding from blood vessels located in difficult-to-compress regions of the body (especially the abdomen, pelvic or groin region) is controlled by the use of a portable, small-footprint belt-like device that contains multiple inflatable bladders. The inflatable bladders are selectively positioned and inflated over exsanguinating blood vessels, thereby exerting pressure to stop the bleeding. The device may also be used to provide perfusion support in low flow disease states such as hemorrhagic shock and cardiac arrest.

Abstract translation: 通过使用便携式，占地面积小的带状装置来控制位于身体难以压缩区域（特别是腹部，骨盆或腹股沟区域）的血管的出血，该装置包含多个充气囊。 可膨胀气囊在放血血管上被选择性定位和充气，从而施加压力以止血。 该装置还可用于在低流量疾病状态（例如出血性休克和心脏骤停）中提供灌注支持。

公开(公告)号：US20160175477A9

公开(公告)日：2016-06-23

申请号：US14445566

申请日：2014-07-29

Applicant: Virginia Commonwealth University ,  The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.

Inventor： Gary Bowlin ,  David Simpson ,  James Bowman ,  Stephen Rothwell

IPC: A61L15/28 ,  A61L15/32 ,  A61L15/44 ,  A61L15/38

CPC classification number: A61L15/28 ,  A61L15/32 ,  A61L15/38 ,  A61L15/44 ,  A61L2300/252 ,  A61L2300/254 ,  A61L2300/418 ,  A61L2400/04 ,  Y10T156/10 ,  C08L5/02

Abstract: The invention generally relates to dextran fibers which are preferably electrospun and devices formed from such fibers. In particular, such devices may include substances of interest (such as therapeutic substances) associated with the electrospun fibers. Upon exposure to a liquid the electrospun fibers dissolve immediately and the substances of interest are released into the liquid. Exemplary devices include bandages formed from electrospun dextran fibers and associated agents that promote hemostasis, such as thrombin and fibrinogen.

公开(公告)号：US20160141333A1

公开(公告)日：2016-05-19

申请号：US14546393

申请日：2014-11-18

Applicant: Virginia Commonwealth University

Inventor： Supriyo Bandyopadhyay ,  Jayasimha Atulasimha ,  Ayan Kumar Biswas

IPC: H01L27/22 ,  G11C11/16 ,  H01L41/047 ,  H01L41/08 ,  H01L43/02 ,  H01L43/08

CPC classification number: H01L27/222 ,  G11C11/15 ,  G11C11/16 ,  G11C11/161 ,  G11C11/1675 ,  G11C11/22 ,  G11C11/2275 ,  G11C11/54 ,  G11C2013/0095 ,  H01L41/047 ,  H01L41/0805 ,  H01L43/02 ,  H01L43/08

Abstract: Memory cells, non-volatile logic gates, and combinations thereof have magneto-tunneling junctions (MTJs) which are switched using potential differences across a piezoelectric layer in elastic contact with a magnetostrictive nanomagnet of an MTJ. One or more pairs of electrodes are arranged about the MTJ for supplying voltage across the piezoelectric layer for switching. A permanent magnetic field may be employed to change the positions of the stable magnetic orientations of the magnetostrictive nanomagnet. Exemplary memory cells and universal non-volatile logic gates show dramatically improved performance characteristics, particularly with respect to energy dissipation and error-resilience, over existing methods and architectures for switching MTJs such as spin transfer torque (STT) techniques.

Abstract translation: 存储单元，非易失性逻辑门及其组合具有使用与MTJ的磁致伸缩纳米磁体弹性接触的压电层上的电位差来切换的磁隧道结（MTJ）。 围绕MTJ布置一对或多对电极，用于在压电层两端提供电压用于切换。 永久磁场可用于改变磁致伸缩纳米磁体的稳定磁取向的位置。 示例性存储器单元和通用非易失性逻辑门显示出显着改进的性能特性，特别是关于能量耗散和错误恢复性的现有方法和结构，用于切换MTJ，例如自旋传递转矩（STT）技术。

公开(公告)号：US20160106866A1

公开(公告)日：2016-04-21

申请号：US14895556

申请日：2014-06-04

Applicant: THE JOHNS HOPKINS UNIVERSITY ,  VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Paul B. FISHER ,  Swadesh K. Das ,  Mitchell E. MENEZES ,  Devanand Sarkar ,  Martin G. Pomper

IPC: A61K48/00 ,  A61K51/00 ,  C12N15/87 ,  A61K49/00 ,  A61K41/00 ,  A61K38/20 ,  C12N7/00

CPC classification number: A61K48/0058 ,  A61K9/0019 ,  A61K38/20 ,  A61K41/0028 ,  A61K41/0033 ,  A61K49/0013 ,  A61K49/0045 ,  A61K49/0054 ,  A61K51/00 ,  A61K51/0491 ,  A61K51/12 ,  C07H21/04 ,  C12N7/00 ,  C12N15/86 ,  C12N15/87 ,  C12N2710/10043 ,  C12N2710/10343 ,  C12N2710/16143 ,  C12N2710/16171 ,  C12N2830/008 ,  C12Q1/6897

Abstract: The presently disclosed subject matter generally relates to genetic constructs and methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols. In particular, the presently disclosed subject matter relates to tripartite cancer theranostic nucleic acid constructs that permit simultaneous cancer specific viral replication, expression of a diagnostic gene product, and expression of a therapeutic gene.

Abstract translation: 目前公开的主题通常涉及其用于癌症成像，癌症治疗和组合成像和治疗方案中的遗传构建体和方法。 特别地，目前公开的主题涉及允许同时进行癌症特异性病毒复制，诊断基因产物的表达和治疗基因表达的三方式癌症核糖核酸构建体。

公开(公告)号：US20160101193A1

公开(公告)日：2016-04-14

申请号：US14895247

申请日：2014-06-04

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Paul B. Fisher ,  Swadesh K. Das ,  Rupesh Dash ,  Devanand Sarkar ,  Siddik Sarkar ,  Jolene Windle

IPC: A61K48/00 ,  A61K49/00 ,  C12N15/86

CPC classification number: A61K48/0058 ,  A01K67/0275 ,  A01K2207/12 ,  A01K2217/052 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/0331 ,  A01K2267/0393 ,  A61K35/761 ,  A61K49/0008 ,  A61K49/005 ,  C12N15/86 ,  C12N2015/8536 ,  C12N2015/8572 ,  C12N2710/10332 ,  C12N2830/008 ,  C12N2830/34

Abstract: Recombinant vectors in which expression of one or more elements (e.g. genes required for viral replication, detectable imaging agents, therapeutic agents, etc.) is driven by a truncated CCN 1 cancer selective promoter (tCCN1-Prom) are provided, as are cells and transgenic animals that contain such vectors. The vectors are used in cancer therapy and/or diagnostics, and the transgenic mice are used to monitor cancer progression, e.g. in screening assays.

Abstract translation: 提供其中一种或多种元件的表达（例如病毒复制所需的基因，可检测的成像剂，治疗剂等）由截短的CCN 1癌选择性启动子（tCCN1-Prom）驱动的重组载体，细胞和 含有这些载体的转基因动物。 这些载体用于癌症治疗和/或诊断，并且转基因小鼠用于监测癌症进展。 在筛选试验中。

公开(公告)号：US20160011207A1

公开(公告)日：2016-01-14

申请号：US14648802

申请日：2013-12-05

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Youngman OH

IPC: G01N33/68 ,  C07K7/06

CPC classification number: G01N33/6893 ,  C07K7/06 ,  G01N2333/47 ,  G01N2333/4745 ,  G01N2800/04 ,  G01N2800/044

Abstract: Methods and compositions for the diagnosis and treatment of chronic inflammation (obesity)-induced disorders such as insulin resistance, diabetes, cancer and various metabolic disorders, are provided. The methods and compositions detect both full-blown disease and early stage disease by detecting proteolysis, by neutrophil proteases, of insulin-like growth factor binding protein-3 (IGFBP3). Levels of proteolytic fragments of IGFBP3 and/or levels of intact IGFPB-3 and/or levels/activity neutrophil proteases are detected. Agents (e.g. peptide agents) that inhibit the proteolysis of IGFPB-3 and methods of using the agents to prevent and treat chronic inflammation (obesity)-induced disorders are also provided.

Abstract translation: 提供了用于诊断和治疗慢性炎症（肥胖）诱导的疾病如胰岛素抵抗，糖尿病，癌症和各种代谢紊乱的方法和组合物。 方法和组合物通过中性粒细胞蛋白酶，胰岛素样生长因子结合蛋白-3（IGFBP3）的蛋白水解检测全发病和早期疾病。 检测IGFBP3的蛋白水解片段水平和/或完整IGFPB-3水平和/或水平/活性嗜中性粒细胞蛋白酶的水平。 还提供了抑制IGFPB-3的蛋白水解的试剂（例如肽试剂）和使用该试剂来预防和治疗慢性炎症（肥胖）诱导的病症的方法。

公开(公告)号：US20160000820A1

公开(公告)日：2016-01-07

申请号：US14790568

申请日：2015-07-02

Applicant: Virginia Commonwealth University

Inventor： Joseph D. Roderique

IPC: A61K31/714 ,  A61M3/00 ,  A61J1/05 ,  A61K9/00

CPC classification number: A61K31/714 ,  A61J1/05 ,  A61J1/2093 ,  A61K9/0019 ,  A61K47/22 ,  A61K2300/00

Abstract: Compositions, methods and kits for treating victims of carbon monoxide and/or cyanide poisoning and/or nitric acid-induced vasoplagia are provided. The compositions comprise reduced forms of Vitamin B12 such as reduced hydroxocobalamin or reduced cobinamide, and typically comprise at least one reducing agent (e.g. ascorbic acid). The compositions are generally produced, stored and delivered under reducing, usually anaerobic, conditions in order to preserve the desired oxidation state when introduced into the blood stream of a recipient.

Abstract translation: 提供了治疗一氧化碳和/或氰化物中毒和/或硝酸诱发的血管扩张的受害者的组合物，方法和试剂盒。 组合物包含减少形式的维生素B12，例如还原的羟钴胺素或还原型共生酰胺，并且通常包含至少一种还原剂（例如抗坏血酸）。 通常在还原性（通常为厌氧）条件下制备，储存和递送组合物，以便在被引入接受者的血液流中时保持所需的氧化状态。